New Releases from NCBI BookshelfUblituximab (multiple sclerosis): Benefit assessment according to §35a SGB V,: IQWiG Reports – Commission No. A24-13 [Internet].​Ublituximab (multiple sclerosis): Benefit assessment according to §35a SGB V,: IQWiG Reports – Commission No. A24-13 [Internet].